Home > Insider Trading > Filing (0001209191-12-031979)

Filing Details

Accession Number:: 0001209191-12-031979
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-06-04 16:54:59
Reporting Period:: 2012-05-22

Filing Date:: 2012-06-04
Accepted Time:: 2012-06-04 16:54:59
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1339455	Somaxon Pharmaceuticals Inc.	SOMX	Pharmaceutical Preparations (2834)	200161599

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134655	Ansbert Gadicke	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1134657	Luke Evnin	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1166285	Michael Steinmetz	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1221595	Iii J Nicholas Simon	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1249153	Dennis Henner	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1252522	Nicholas Galakatos	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No
1252525	Kurt Wheeler	C/O Mpm Asset Management 200 Clarendon St., 54Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-05-22	287,000	$0.30	4,345,562	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2012-05-23	135,250	$0.30	4,210,312	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2012-05-25	293,015	$0.30	3,917,297	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2012-05-29	15,300	$0.30	3,901,997	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2012-05-30	51,007	$0.30	3,850,990	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2012-05-31	29,850	$0.30	3,821,140	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares were sold as follows: 239,235 by MPM BioVentures III-QP, L.P. ("BV III QP"), 16,086 by MPM BioVentures III, L.P. ("BV III"), 4,236 by MPM Asset Management Investors 2005 BVIII LLC ("AM 2005"), 7,227 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 20,216 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III, BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the Series A members of MPM III LLC and the managers of AM 2005.
The shares are held as follows: 3,622,311 by BV III QP, 243,568 by BV III, 64,163 by AM 2005, 109,419 by BV Parallel and 306,101 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 112,740 by BV III QP, 7,581 by BV III, 1,996 by AM 2005, 3,406 by BV Parallel and 9,527 by BV KG.
The shares are held as follows: 3,509,571 by BV III QP, 235,987 by BV III, 62,167 by AM 2005, 106,013 by BV Parallel and 296,574 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 244,249 by BV III QP, 16,423 by BV III, 4,325 by AM 2005, 7,378 by BV Parallel and 20,640 by BV KG.
The shares are held as follows: 3,265,322 by BV III QP, 219,564 by BV III, 57,842 by AM 2005, 98,635 by BV Parallel and 275,934 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 12,754 by BV III QP, 857 by BV III, 226 by AM 2005, 385 by BV Parallel and 1,078 by BV KG.
The shares are held as follows: 3,252,568 by BV III QP, 218,707 by BV III, 57,616 by AM 2005, 98,250 by BV Parallel and 274,856 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 42,518 by BV III QP, 2,859 by BV III, 753 by AM 2005, 1,284 by BV Parallel and 3,593 by BV KG.
The shares are held as follows: 3,210,050 by BV III QP, 215,848 by BV III, 56,863 by AM 2005, 96,966 by BV Parallel and 271,263 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
The shares were sold as follows: 24,882 by BV III QP, 1,673 by BV III, 440 by AM 2005, 752 by BV Parallel and 2,103 by BV KG.
The shares are held as follows: 3,185,168 by BV III QP, 214,175 by BV III, 56,423 by AM 2005, 96,214 by BV Parallel and 269,160 by BV KG. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.